|
|
Vaccine Detail
|
HDT-301 |
| Vaccine Information |
- Vaccine Name: HDT-301
- Target Pathogen: SARS-CoV-2
- Target Disease: COVID-19
- Product Name: repRNA-CoV2S
- Manufacturer: SENAI CIMATEC
- Vaccine Ontology ID: VO_0005256
- Type: mRNA vaccine
- Status: Clinical trial
- Host Species for Licensed Use: Human
- Host Species as Laboratory Animal Model: Mouse
- Antigen: full-length spike (S) protein
- Immunization Route: Intramuscular injection (i.m.)
- Description: Alphavirus-derived replicon RNA vaccine candidate, repRNA-CoV2S, encoding the SARS-CoV-2 spike (S) protein. The RNA replicons were formulated with lipid inorganic nanoparticles (LIONs) that were designed to enhance vaccine stability, delivery, and immunogenicity. (Erasmus et al., 2020)
|
| Host Response |
|
|
| References |
Erasmus et al., 2020: Erasmus JH, Khandhar AP, O'Connor MA, Walls AC, Hemann EA, Murapa P, Archer J, Leventhal S, Fuller JT, Lewis TB, Draves KE, Randall S, Guerriero KA, Duthie MS, Carter D, Reed SG, Hawman DW, Feldmann H, Gale M Jr, Veesler D, Berglund P, Fuller DH. An Alphavirus-derived replicon RNA vaccine induces SARS-CoV-2 neutralizing antibody and T cell responses in mice and nonhuman primates. Science translational medicine. 2020; 12(555); . [PubMed: 32690628].
|
|
